Adverse Events with EMAs: Luspatercept
Dr Garcia-Manero offers insights on the adverse events profile associated with luspatercept in patients with lower-risk MDS.
Video content above is prompted by the following:
- Please discuss the adverse events profile associated with luspatercept for any grade and ≥ grade 3 AEs.
- Which AEs are most concerning? Are hematologic or non-hematologic most common?
- How do you manage these events in your practice? Do the AEs have a significant impact on quality of life for patients?
Recent Videos
Related Content
Exploring Factors Supporting TKI Discontinuation in Patients With Ph+ ALL
June 27th 2025Article
Recent studies reveal promising outcomes for discontinuing TKI therapy in select patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, suggesting potential long-term remission.
Read More
